Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
-0.005 (-4.35%)
Oct 22 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range 0.11 - 0.11
52 week 0.08 - 0.24
Open 0.11
Vol. 23,000.00
Mkt cap 10.11M
P/E     -
Div/yield     -
EPS -0.06
Shares 91.92M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -2944.55% -975.77%
Operating margin -2735.61% -963.96%
EBITD margin - -945.34%
Return on average assets -158.46% -156.44%
Return on average equity - -1478.00%
CDP Score - -


Unit 10, 81 Zenway Blvd
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics, Inc. is a Canada-based pharmaceutical company with a focus on cardiovascular health. The Company offers VASCAZENTM, is a prescription grade, ultra-pure Omega 3 fatty acid for the dietary management of cardiovascular disease in patients manifesting an Omega 3 fatty acid deficiency. VASCAZENTM is manufactured according to FDA (Food and Drug Administration) current Good Manufacturing Practices (cGMP) and each capsule of VASCAZENTM provides 680 mg of Eicosapentaenoic (EPA) and 110 mg of Eicosapentaenoic (EPA), for oral administration.

Officers and directors

Rachelle MacSweeney President, Director
Prakash Gowd Chief Financial Officer
Age: 48
George Jackowski Ph.D. Chief Scientific Officer, Director
Eugene G. Bortoluzzi Chief Executive Officer, Director
John S. Gebhardt Non-Executive Chairman of the Board
Age: 66
James J. Carey Independent Director
Giuseppe Simeone Independent Director